From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Coca-Cola Launches Lens Platform to Offer Key Data for Retail and Foodservice 
McDonald's Faces Backlash Over $5 Meal Deal: Customers Call It 'Skimpy' 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
Green industry yes, conservation no: a budget for people, not for nature 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
The 2023 Sir Paul Curran award for academic journalism goes to Barbara Sahakian 
ECB Calls for Monitoring and Possible Regulation of AI in Finance 
Converse Faces Job Cuts as Nike Aims for $2 Billion in Cost Savings 
Skepta and PUMA Launch Groundbreaking Collection 
NEW YORK, Sept. 08, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Dr. Reddy’s Laboratories Ltd. ("Dr. Reddy’s") (NYSE:RDY) securities between June 17, 2015 and August 10, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/dr-reddys-laboratories-ltd?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Dr. Reddy’s lacked an effective corporate quality system; and (2) as a result, defendants’ public statements were materially false and misleading at all relevant times. On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India.
If you suffered a loss in Dr. Reddy’s you have until October 24, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/dr-reddys-laboratories-ltd?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
